Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) EPS (Basic): 2010-2025

Historic EPS (Basic) for Sunshine Biopharma (SBFM) over the last 6 years, with Sep 2025 value amounting to -$0.19.

  • Sunshine Biopharma's EPS (Basic) rose 79.79% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.27, marking a year-over-year increase of 105.35%. This contributed to the annual value of -$7.32 for FY2024, which is 97.92% up from last year.
  • Latest data reveals that Sunshine Biopharma reported EPS (Basic) of -$0.19 as of Q3 2025, which was up 51.28% from -$0.39 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's EPS (Basic) registered a high of $6.29 during Q4 2024, and its lowest value of -$2,082 during Q4 2022.
  • For the 3-year period, Sunshine Biopharma's EPS (Basic) averaged around -$20.26, with its median value being -$2 (2024).
  • Per our database at Business Quant, Sunshine Biopharma's EPS (Basic) skyrocketed by 135.66% in 2021 and then slumped by 237,133.33% in 2023.
  • Sunshine Biopharma's EPS (Basic) (Quarterly) stood at $0.97 in 2021, then plummeted by 214,741.81% to -$2,082 in 2022, then soared by 95.89% to -$85.65 in 2023, then skyrocketed by 107.34% to $6.29 in 2024, then soared by 79.79% to -$0.19 in 2025.
  • Its EPS (Basic) stands at -$0.19 for Q3 2025, versus -$0.39 for Q2 2025 and -$0.44 for Q1 2025.